Joseph Nester

Chief Operations Officer, Mr. Nester’s received a BBA from the University of Texas at Austin in 1980 and has worked in bank regulation, commercial banking, and pharmaceutical research and development for 40+ years. More than half of this time has been associated with the research of the Nerium oleander plant and one of its primary therapeutic compounds, oleandrin. As the president of Ozelle Pharmaceuticals, Mr. Nester was successful in obtaining the first-ever Compassionate Use Investigational New Drug (CUIND) approval on “Anvirzel” prior to initiation of any human clinical studies. That company went on to have a successful Phase 1 study performed at the Cleveland Clinic where Anvirzel was found to be safe with intramuscular injection administration of up to 2.4ml per day. Since then, Mr. Nester has been involved in the research, development, and marketing of many oleander-based products.